Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials

Infection and Immunity

Volumn 77, Issue 5, 2009, Pages 2022-2029

  Maurer Cecchini, Anne ^a   Decuypere, Saskia ^b   Chappuis, François ^a   Alexandrenne, Coralie ^a   De Doncker, Simonne ^b   Boelaert, Marleen ^b   Dujardin, Jean Claude ^b   Loutan, Louis ^a   Dayer, Jean Michel ^a   Tulliano, Gianfranco ^c   Arevalo, Jorge ^c   Llanos Cuentas, Alexandro ^c   Chizzolini, Carlo ^a,d  

^a University Hospital and Faculty of Medicine   (Switzerland)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MEGLUMINE; STIBOGLUCONATE SODIUM; TUMOR NECROSIS FACTOR; ANTIMONY; ANTIPROTOZOAL AGENT; CYTOKINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; INFANT; LEISHMANIA; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SKIN LEISHMANIASIS; T LYMPHOCYTE; TREATMENT OUTCOME; WORM TEGUMENT; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION PROFILING; IMMUNOLOGY; MACROPHAGE; MIDDLE AGED; PATHOLOGY; PERU; PROSPECTIVE STUDY; SKIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFANT; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MALE; MIDDLE AGED; PERU; PROSPECTIVE STUDIES; SKIN; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65449185486     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01513-08     Document Type: Article

References (48)

1. Alexander, J., F. Brombacher, H. A. McGachy, A. N. McKenzie, W. Walker, and K. C. Carter. 2002. An essential role for IL-13 in maintaining a nonhealing response following Leishmania mexicana infection. Eur. J. Immunol. 32:2923-2933. (Pubitemid 35238186)
2. Alexander, J., and K. Bryson. 2005. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol. Lett. 99:17-23.
3. Amato, V. S., H. F. de Andrade, and M. I. Duarte. 2003. Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment. Acta Trop. 85:39-49.
4. Arevalo, J., L. Ramirez, V. Adaui, M. Zimic, G. Tulliano, C. Miranda-Verastegui, M. Lazo, R. Loayza-Muro, S. De Doncker, A. Maurer, F. Chappuis, J. C. Dujardin, and A. Llanos-Cuentas. 2007. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J. Infect. Dis. 195:1846-1851. (Pubitemid 46870258)
5. Bacellar, O., H. Lessa, A. Schriefer, P. Machado, A. Ribeiro de Jesus, W. O. Dutra, K. J. Gollob, and E. M. Carvalho. 2002. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect. Immun. 70:6734-6740. (Pubitemid 35387904)
6. Banerjee, A., M. De, and N. Ali. 2008. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J. Immunol. 181:1386-1398.
7. Bourreau, E., G. Prevot, J. Gardon, R. Pradinaud, and P. Launois. 2001. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J. Infect. Dis. 184:1628-1630. (Pubitemid 33139754)
8. + T cells unresponsive to IL-12. J. Infect. Dis. 183:953-959.
9. Cáceres-Dittmar, G., F. J. Tapia, M. A. Sanchez, M. Yamamura, K. Uyemura, R. L. Modlin, B. R. Bloom, and J. Convit. 1993. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin. Exp. Immunol. 91:500-505. (Pubitemid 23074159)
10. + T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J. Infect. Dis. 193:1313-1322.
11. Castes, M., D. Trujillo, M. E. Rojas, C. T. Fernandez, L. Araya, M. Cabrera, J. Blackwell, and J. Convit. 1993. Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biol. Res. 26:233-238. (Pubitemid 24109052)
12. Choi, C. M., and E. A. Lerner. 2002. Leishmaniasis: recognition and management with a focus on the immunocompromised patient. Am. J. Clin. Dermatol. 3:91-105.
13. Croft, S. L., S. Sundar, and A. H. Fairlamb. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126. (Pubitemid 43157649)
14. Faria, D. R., K. J. Gollob, J. Barbosa, Jr., A. Schriefer, P. R. Machado, H. Lessa, L. P. Carvalho, M. A. Romano-Silva, A. R. de Jesus, E. M. Carvalho, and W. O. Dutra. 2005. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect. Immun. 73:7853-7859. (Pubitemid 41740268)
15. Franke, E. D., F. S. Wignall, M. E. Cruz, E. Rosales, A. A. Tovar, C. M. Lucas, A. Llanos-Cuentas, and J. D. Berman. 1990. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann. Intern. Med. 113:934-940.
16. Grogl, M., T. N. Thomason, and E. D. Franke. 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:117-126.
17. Gumy, A., J. A. Louis, and P. Launois. 2004. The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. Int. J. Parasitol. 34:433-444. (Pubitemid 38317168)
18. Joshi, P. B., B. L. Kelly, S. Kamhawi, D. L. Sacks, and W. R. McMaster. 2002. Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol. Biochem. Parasitol. 120:33-40. (Pubitemid 34159290)
19. Llanos-Cuentas, A., G. Tulliano, R. Araujo-Castillo, C. Miranda-Verastegui, G. Santamaria-Castrellon, L. Ramirez, M. Lazo, S. De Doncker, M. Boelaert, J. Robays, J. C. Dujardin, J. Arevalo, and F. Chappuis. 2008. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin. Infect. Dis. 46:223-231.
20. Louzir, H., P. C. Melby, A. Ben Salah, H. Marrakchi, K. Aoun, R. Ben Ismail, and K. Dellagi. 1998. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J. Infect. Dis. 177:1687-1695. (Pubitemid 28243596)
21. Machado, P., C. Araujo, A. T. Da Silva, R. P. Almeida, A. D'Oliveira, Jr., A. Bittencourt, and E. M. Carvalho. 2002. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin. Infect. Dis. 34:E69-E73.
22. Matthews, D. J., C. L. Emson, G. J. McKenzie, H. E. Jolin, J. M. Blackwell, and A. N. McKenzie. 2000. IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 164:1458-1462. (Pubitemid 30067261)
23. McMahon-Pratt, D., and J. Alexander. 2004. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol. Rev. 201:206-224. (Pubitemid 39318454)
24. Melby, P. C., F. J. Andrade-Narvaez, B. J. Darnell, G. Valencia-Pacheco, V. V. Tryon, and A. Palomo-Cetina. 1994. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 62:837-842. (Pubitemid 24065562)
25. + regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J. Exp. Med. 200:201-210.
26. Mimori, T., Y. Hashiguchi, M. Kawabata, E. A. Gomez, and V. V. De Coronel. 1987. The relationship between severity of ulcerated lesions and immune responses in the early stage of cutaneous leishmaniasis in Ecuador. Ann. Trop. Med. Parasitol. 81:681-685. (Pubitemid 18073229)
27. Murray, H. W., J. D. Berman, C. R. Davies, and N. G. Saravia. 2005. Advances in leishmaniasis. Lancet 366:1561-1577.
28. Nashed, B. F., Y. Maekawa, M. Takashima, T. Zhang, K. Ishii, T. Dainichi, H. Ishikawa, T. Sakai, H. Hisaeda, and K. Himeno. 2000. Different cytokines are required for induction and maintenance of the Th2 type response in DBA/2 mice resistant to infection with Leishmania major. Microbes Infect. 2:1435-1443.
29. Noben-Trauth, N., R. Lira, H. Nagase, W. E. Paul, and D. L. Sacks. 2003. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170:5152-5158. (Pubitemid 36554747)
30. + (Foxp3) regulatory T cells in human visceral leishmaniasis. J. Exp. Med. 204:805-817.
31. Padigel, U. M., J. Alexander, and J. P. Farrell. 2003. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 171:3705-3710. (Pubitemid 37254575)
32. Passos, V. M., S. M. Barreto, A. J. Romanha, A. U. Krettli, A. C. Volpini, and M. F. Lima e Costa. 2000. American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment. Bull. W. H. O. 78:968-974.
33. Peters, N., and D. Sacks. 2006. Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol. Rev. 213:159-179.
34. Pirmez, C., M. Yamamura, K. Uyemura, M. Paes-Oliveira, F. Conceicao-Silva, and R. L. Modlin. 1993. Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Investig. 91:1390-1395. (Pubitemid 23127337)
35. Qi, H., J. Ji, N. Wanasen, and L. Soong. 2004. Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. Infect. Immun. 72:988-995.
36. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-177.
37. Rijal, S., F. Chappuis, R. Singh, P. A. Bovier, P. Acharya, B. M. Karki, M. L. Das, P. Desjeux, L. Loutan, and S. Koirala. 2003. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg. 97:350-354.
38. Rocha, F. J., U. Schleicher, J. Mattner, G. Alber, and C. Bogdan. 2007. Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice. Infect. Immun. 75:3823-3832. (Pubitemid 47206279)
39. Romero, G. A., M. V. Guerra, M. G. Paes, and V. O. Macedo. 2001. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am. J. Trop. Med. Hyg. 65:456-465.
40. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845-858. (Pubitemid 37328707)
41. Salhi, A., V. Rodrigues, Jr., F. Santoro, H. Dessein, A. Romano, L. R. Castellano, M. Sertorio, S. Rafati, C. Chevillard, A. Prata, A. Alcais, L. Argiro, and A. Dessein. 2008. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J. Immunol. 180:6139-6148.
42. Schwartz, E., C. Hatz, and J. Blum. 2006. New World cutaneous leishmaniasis in travellers. Lancet Infect. Dis. 6:342-349. (Pubitemid 43737272)
43. Sereno, D., E. Guilvard, S. Maquaire, M. Cavaleyra, P. Holzmuller, A. Ouaissi, and J. L. Lemesre. 2001. Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: implications for the spread of chemoresistance in endemic areas. Acta Trop. 80:195-205.
44. Späth, G. F., L. Epstein, B. Leader, S. M. Singer, H. A. Avila, S. J. Turco, and S. M. Beverley. 2000. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc. Natl. Acad. Sci. USA 97:9258-9263.
45. Trinchieri, G. 2007. Interleukin-10 production by effector T cells: Th1 cells show self control. J. Exp. Med. 204:239-243.
46. Vandesompele, J., K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe, and F. Speleman. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3:RESEARCH0034.
47. von Stebut, E., and M. C. Udey. 2004. Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect. 6:1102-1109. (Pubitemid 39233683)
48. Yardley, V., N. Ortuno, A. Llanos-Cuentas, F. Chappuis, S. D. Doncker, L. Ramirez, S. Croft, J. Arevalo, V. Adaui, H. Bermudez, S. Decuypere, and J. C. Dujardin. 2006. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J. Infect. Dis. 194:1168-1175.